Key Clinical Investigators
Our key clinical investigators are those directly involved in the ongoing and forthcoming clinical trials in Autoimmunity/Inflammation. Leaders include those who specialise in Lupus and CIDP.
Professor David Isenberg
Prof. Isenberg’s principal clinical interests have been in the development of disease activity and damage assessment tools in patients with lupus. Chair of the British Isles Assessment Group and also the Chair (1998-2003) of the Systemic Lupus International Collaborating Clinics group (SLICC). He is the Professor of Rheumatology, University College Hospital, London.Read more..
Prof. Isenberg has undertaken many roles for the arc in the past 20 years and is the past president of the British Society for Rheumatology (2004-2006) and is currently chairing the Society’s Biologics Register Committee. He is the 2010 recipient of the Evelyn Hess Prize from the Lupus Foundation of America for his contribution to lupus research and treatment.
Professor Jérôme de Sèze
Head of the Neuroimmunological Department, University of Strasbourg, FR Program: CIDP ((Chronic Inflammatory Demyelinating Polyneuropathy)
Professor De Seze has been instrumental in guiding the development of our Phase 2/3 adaptive clinical trial in CIDP. This will be a pivotal trial suitable for registration. Next steps are the IND submission to the FDA and an application for orphan drug designation. We would expect to commence this trial in 2023.Read more..
Professor Jerome de Seze is a Professor in Neurology and PhD in Immunology and Head of the Neuroimmunological department of Strasbourg hospital. He is a recognised specialist in CIDP and principal investigator for our forthcoming CIDP trial and has been involved in many CIDP trials. Professor Sylviane Muller, who has a longstanding relationship with Professor de Seze and his work within CIDP, will provide any necessary support for this programme.
This CIDP programme is also expected to be designated as an orphan drug indication, which has many advantages in terms of its regulatory pathway to market and subsequent market exclusivity. In addition, this programme has much shorter clinical timelines than our Lupus programme, meaning that this clinical trial could complete ahead of our Lupuzor™ Phase 3 trial and potentially reach registration and commercialisation up to a year earlier than the Lupus indication.
The CIDP programme is gaining a lot of interest from pharmaceutical companies who are attracted to orphan indications and who specialise in the Neuropathy area. We are currently in active discussions with two potential commercial partners.
For more information go to: https://www.futureproofinghealthcare.com/en/experts-think/experts/professor-jerome-de-seze